Company

Vaxxas

Vaxxas is a private Brisbane biotechnology company developing a high-density microarray patch (HD-MAP), a needle-free vaccine delivery device derived from University of Queensland research. The patch carries thousands of vaccine-coated microprojections that are pressed into the skin for a few seconds, depositing vaccine into the immune-cell-rich layer immediately below the surface rather than into muscle. The claimed advantages are dose-sparing, reduced cold-chain dependence, and the possibility of self-administration at home. It meets the inclusion rule on limb (b), Australian headquarters, and the company confirms it is private (Vaxxas Pty Ltd, Series D equity plus debt, August 2025). The longevity link is indirect and should be read that way: Vaxxas is a delivery platform, not a therapeutic, and makes no ageing-biology claim. The relevance to a longevity universe is preventive-health and immunosenescence adjacency, since intradermal delivery is the route most often studied for improving vaccine response in older adults whose immune systems respond poorly to intramuscular injection, and since a lower-cost, cold-chain-light delivery format bears on population-scale preventive coverage. Vaxxas has not published a specific older-adult immunogenicity programme that was verifiable from the sources opened here. Treat it as peripheral to the core longevity thesis.

At a glance

Listing: Private, not listed
Category: Healthtech
Headquarters: Brisbane, Queensland, Australia
Market cap: Not disclosed

Thesis

Why it is in this universe

Category: Healthtech
Market: Australia
Recent inflection: On 25 August 2025 Vaxxas announced approximately A$90 million in new financing, comprising A$49.22 million of Series D equity and A$40 million in debt facilities, led by SPRIM Global Investments with participation from new investor LGT Crestone and existing investors OneVentures and Brandon Capital-Hostplus. The company said the round funds semi-automated manufacturing lines and later-stage clinical trials and provides runway into the second half of 2027, and that founding CEO David Hoey would move to a strategic advisor role. Source: GlobeNewswire release, 25 August 2025. Subsequent company-disclosed milestones on vaxxas.com/news include a TGA manufacturing licence (15 December 2025), the appointment of David Peacock, formerly of Merck's global vaccines division, as CEO (8 January 2026), and participation in a consortium awarded an EU tender for next-generation influenza vaccines (26 February 2026).
Services: None recorded
People tracked: None on file

Market data

Listing and scale

Metric	Detail
Exchange	Unlisted
Ticker	None
Secondary listing	None
Market cap	Not disclosed
Status	Private

Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.

Get in touch

Contact

Address: Brisbane, Queensland, Australia
Website: www.vaxxas.com
Phone: No public number published
Email: No public address published

Offering

What it sells today

No commercial services are recorded for this company yet.

Recent inflection

What moved lately

On 25 August 2025 Vaxxas announced approximately A$90 million in new financing, comprising A$49.22 million of Series D equity and A$40 million in debt facilities, led by SPRIM Global Investments with participation from new investor LGT Crestone and existing investors OneVentures and Brandon Capital-Hostplus. The company said the round funds semi-automated manufacturing lines and later-stage clinical trials and provides runway into the second half of 2027, and that founding CEO David Hoey would move to a strategic advisor role. Source: GlobeNewswire release, 25 August 2025. Subsequent company-disclosed milestones on vaxxas.com/news include a TGA manufacturing licence (15 December 2025), the appointment of David Peacock, formerly of Merck's global vaccines division, as CEO (8 January 2026), and participation in a consortium awarded an EU tender for next-generation influenza vaccines (26 February 2026).

Common questions

Why does variis track Vaxxas?: Vaxxas is a private Brisbane biotechnology company developing a high-density microarray patch (HD-MAP), a needle-free vaccine delivery device derived from University of Queensland research. The patch carries thousands of vaccine-coated microprojections that are pressed into the skin for a few seconds, depositing vaccine into the immune-cell-rich layer immediately below the surface rather than into muscle. The claimed advantages are dose-sparing, reduced cold-chain dependence, and the possibility of self-administration at home. It meets the inclusion rule on limb (b), Australian headquarters, and the company confirms it is private (Vaxxas Pty Ltd, Series D equity plus debt, August 2025). The longevity link is indirect and should be read that way: Vaxxas is a delivery platform, not a therapeutic, and makes no ageing-biology claim. The relevance to a longevity universe is preventive-health and immunosenescence adjacency, since intradermal delivery is the route most often studied for improving vaccine response in older adults whose immune systems respond poorly to intramuscular injection, and since a lower-cost, cold-chain-light delivery format bears on population-scale preventive coverage. Vaxxas has not published a specific older-adult immunogenicity programme that was verifiable from the sources opened here. Treat it as peripheral to the core longevity thesis.
Is Vaxxas publicly listed?: variis has no ticker on file for Vaxxas, so it is tracked as private or unlisted. Absence of a ticker on this record is not a statement that no listing exists anywhere.
Where is Vaxxas based?: Brisbane, Queensland, Australia
Is Vaxxas still trading?: Vaxxas is recorded as private.

Keep reading

Related coverage from the newsroom.

Singapore and Australia · Capital

Two rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 2026

Suggest an update

Sources

What this profile is built on

Vaxxas: HD-MAP needle-free vaccination technology · Vaxxas
Vaxxas news archive (2025-2026 milestones) · Vaxxas
Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology · GlobeNewswire

Last updated 14 August 2026

Every entity profile on variis is sourced. Not investment advice.

Metric

Detail

Exchange

Unlisted

Ticker

None

Secondary listing

None

Market cap

Not disclosed

Status

Private

What moved lately

Common questions

Why does variis track Vaxxas?

Vaxxas is a private Brisbane biotechnology company developing a high-density microarray patch (HD-MAP), a needle-free vaccine delivery device derived from University of Queensland research. The patch carries thousands of vaccine-coated microprojections that are pressed into the skin for a few seconds, depositing vaccine into the immune-cell-rich layer immediately below the surface rather than into muscle. The claimed advantages are dose-sparing, reduced cold-chain dependence, and the possibility of self-administration at home. It meets the inclusion rule on limb (b), Australian headquarters, and the company confirms it is private (Vaxxas Pty Ltd, Series D equity plus debt, August 2025). The longevity link is indirect and should be read that way: Vaxxas is a delivery platform, not a therapeutic, and makes no ageing-biology claim. The relevance to a longevity universe is preventive-health and immunosenescence adjacency, since intradermal delivery is the route most often studied for improving vaccine response in older adults whose immune systems respond poorly to intramuscular injection, and since a lower-cost, cold-chain-light delivery format bears on population-scale preventive coverage. Vaxxas has not published a specific older-adult immunogenicity programme that was verifiable from the sources opened here. Treat it as peripheral to the core longevity thesis.

Is Vaxxas publicly listed?

variis has no ticker on file for Vaxxas, so it is tracked as private or unlisted. Absence of a ticker on this record is not a statement that no listing exists anywhere.

Where is Vaxxas based?

Brisbane, Queensland, Australia

Is Vaxxas still trading?

Vaxxas is recorded as private.